IPN 📈 Ipsen SA - Overview

Ipsen SA is a global biopharmaceutical company that develops and markets a range of innovative treatments for various diseases. The company's product portfolio spans multiple therapeutic areas, including oncology, neuroscience, and rare diseases. In oncology, Ipsen offers a variety of treatments, such as Somatuline, Decapeptyl, Cabometyx, Onivyde, and Tazverik, which are used to treat different types of cancer. Additionally, the company has a robust pipeline of oncology products in development, including Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer.

In the area of neuroscience, Ipsen provides treatments for various conditions, including Dysport, which is used to treat chronic and episodic migraine, as well as other neurosciences products. The company is also developing new treatments for neurological disorders, such as IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics. Furthermore, Ipsen has a strong focus on rare diseases, offering treatments like Bylvay, NutropinAq, Increlex, and Sohonos. The company's pipeline for rare diseases includes Bylvay, which is in phase III for the treatment of biliary atresia, and Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva.

Ipsen SA has a long history, dating back to 1929, and is headquartered in Boulogne-Billancourt, France. The company's commitment to innovation and patient care is reflected in its extensive research and development efforts, with multiple products in various stages of clinical trials. Ipsen's product pipeline includes IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, and IPN60260, which is in phase I clinical trial for the treatment of Viral cholestatic disease. With a strong foundation in biopharmaceuticals and a dedication to improving patient outcomes, Ipsen SA continues to evolve and expand its portfolio of treatments for various diseases.

As a publicly traded company, Ipsen SA is listed on the Euronext Paris stock exchange under the ticker symbol IPN, with the ISIN code FR0010259150. The company's common stock is classified under the GICS Sub Industry: Pharmaceuticals. With a global presence and a diverse range of products, Ipsen SA is a significant player in the biopharmaceutical industry, with a website available at https://www.ipsen.com. The company's ongoing research and development efforts, combined with its existing product portfolio, position Ipsen SA for continued growth and innovation in the biopharmaceutical sector.